Trius Therapeutics (Nasdaq: TSRX) was a biopharma company based in San Diego, CA that focused on the development of antibiotics.
[2] It is a once daily, IV and oral, oxazolidinone being developed for the treatment of serious gram-positive infections, including those caused by methicillin-resistant Staphylococcus aureus (MRSA).
[3] The Phase 3 trials are being conducted under a Special Protocol Agreement with the US Food and Drug Administration and are using the draft FDA guidance of cessations of lesion spread at 48–72 hours as the primary endpoint.
The work included a collaboration with the Lawrence Livermore National Laboratory to help identify antibiotics against gram-negative infections and bioterrorism.
[13] In 2011 Bayer acquired the exclusive rights to Trius' antibiotic tedizolid in certain areas in Asia, Africa, the Middle East, and Latin America.